Biotechnology therapy for osteoarthritis
Promising new biotechnology-based treatments for osteoarthritis are achieving both symptom control and modification of disease progression.
Arthritis is a major cause of disability and chronic pain in Australia.
It is estimated that at least 3.85 million people are affected across the Australian community, at an annual cost to our economy of more than $23.9 billion.
With an ageing population, modelling predicts more than seven million Australians will suffer from symptomatic arthritis by 2050.
Importantly, while recognised as a progressive condition, osteoarthritis (OA) does not discriminate on the basis of age and can affect both the young and old.
A significant proportion of people with arthritis are of working age.
In recent years, medical management of inflammatory arthropathies such as rheumatoid arthritis has improved significantly through the development of